quinazolines has been researched along with Central Nervous System Neoplasm in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (26.47) | 29.6817 |
| 2010's | 25 (73.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Goldman, JW; Harrop, B; John, T; Kao, S; Kim, DW; Kim, HR; Kim, SW; Kim, TM; Lee, JS; Lin, CC; Natale, R; Overend, P; Rabbie, S; Su, WC; Yang, JC; Yang, Z | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Geyer, JR; Gilbertson, RJ; Goldman, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Jang, SH; Jang, TW; Kim, HJ; Kim, HR; Kim, KS; Kim, SY; Kim, YC; Lee, GH; Lee, JC; Lee, JE; Lee, KY; Lee, MK; Lee, SY; Oh, IJ; Ryu, JS; Shin, KC; Son, JW | 1 |
| Cavenee, WK; Cloughesy, TF; Eskin, A; Furnari, FB; Gini, B; Gomez, G; Heath, JR; Hwang, K; James, CD; Koga, T; Kornblum, HI; Masui, K; Mischel, PS; Mottahedeh, J; Nathanson, DA; Nelson, SF; Ohashi, M; Paucar, A; Rao, PN; Reed, R; Visnyei, K; Wang, J; Wykosky, J; Yang, H; Zhu, S | 1 |
| D'Almeida Costa, F; de Fátima Bonaldo, M; Patel, K; Sredni, ST; Tomita, T | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Crinò, L; Foglietta, J; Gori, S; Metro, G | 1 |
| Banerjee, A; Boyett, JM; Chi, S; Fahey, F; Fouladi, M; Goldman, S; Jakacki, R; Kieran, MW; Kun, L; Moses, M; Onar-Thomas, A; Packer, RJ; Poussaint, TY; Stewart, CF; Turner, DC; Vajapeyam, S; Wu, S | 1 |
| Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Kaelin, W; LoRusso, P; Malik, G; Nadler, P; Rogers, LR; Shields, A | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Gilbertson, RJ; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y; Tsuchido, Y | 1 |
| Clarke, JL; Grommes, C; Holodny, AI; Kris, MG; Lassman, AB; Miller, VA; Oxnard, GR; Pao, W | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Chi, SN; Forsyth, P; Jayanthan, A; Lun, X; Narendran, A; Obaid, H; Ruan, Y; Singh, A; Smith, A; Strother, D | 1 |
| Hoang-Xuan, K; Sanson, M; Thillet, J | 1 |
| Cappuzzo, F | 1 |
| Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Moreno, M; Perez-Gracia, JL; Zubieta, JL | 1 |
| Donson, AM; Foreman, NK; Gore, L; Heideman, R; Straessle, J; Wells, D | 1 |
| Bigner, DD; Dimery, I; Friedman, HS; Graner, MW; Kaipainen, A; Keir, ST; Kieran, MW; Laforme, A; McLendon, RE; Rasheed, BK; Reardon, DA; Rich, JN; Ryan, AJ; Sathornsumetee, S; Wang, L; Wheeler, C | 1 |
| Stummer, W | 1 |
| Engelman, JA; Evans, TL; Goldberg, JS; Grunberg, SM; Haber, DA; Han, M; Iafrate, AJ; Jänne, PA; Johnson, BE; Joshi, VA; Kuhlmann, GL; Lynch, TJ; Martins, RG; McCollum, D; Muzikansky, A; Sequist, LV; Settleman, J; Spigel, D; Spira, A | 1 |
| Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G | 1 |
4 review(s) available for quinazolines and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Molecular changes in gliomas.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Epidermal Growth Factor; Gefitinib; Glioma; Humans; Neovascularization, Pathologic; Quinazolines | 2004 |
Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Radiography | 2005 |
8 trial(s) available for quinazolines and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Piperazines; Quinazolines; Republic of Korea; Taiwan; Treatment Outcome; United States | 2017 |
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Topics: Adolescent; Antineoplastic Agents; Blotting, Western; Central Nervous System Neoplasms; Child; Child, Preschool; Ependymoma; ErbB Receptors; Female; Glioma; Humans; Infant; Lapatinib; Male; Medulloblastoma; Neoplasm Grading; Quinazolines; Treatment Outcome; Young Adult | 2013 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
Topics: Administration, Oral; Adolescent; Biological Availability; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic; Time Factors; Young Adult | 2015 |
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2010 |
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diarrhea; ErbB Receptors; Exanthema; Fatigue; Female; Humans; Infant; Lapatinib; Male; Maximum Tolerated Dose; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Steroids; Treatment Outcome; United States; Young Adult | 2010 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
22 other study(ies) available for quinazolines and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Survival Analysis | 2014 |
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Single-Cell Analysis; Tumor Cells, Cultured; Withholding Treatment | 2014 |
Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; ErbB Receptors; Female; Humans; Male; Quinazolines | 2014 |
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Central Nervous System Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Maytansine; Quinazolines | 2015 |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord | 2016 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.
Topics: Adult; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Hemangioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; von Hippel-Lindau Disease | 2011 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cells, Cultured; Central Nervous System Neoplasms; Child; ErbB Receptors; Female; Humans; Infant; Lapatinib; Male; Mice; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Rhabdoid Tumor; Signal Transduction | 2013 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
Topics: Astrocytoma; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Profiling; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Thymidine; Tumor Cells, Cultured | 2006 |
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Ependymoma; ErbB Receptors; Glioma; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Perspectives in central nervous system malignancies.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2006 |
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Survival Analysis; Survival Rate; Temozolomide | 2002 |